Prevalence of Cannabinoid Use in Patients With Hip and Knee Osteoarthritis

Deckey, David G.; Lara, Nina; Gulbrandsen, Matthew T; Hassebrock, Jeffrey D.; Spangehl, Mark J.; Bingham, Joshua S.

doi:10.5435/jaaosglobal-d-20-00172

Cited by 10 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the respondents, 176 (30%) patients with arthritis had not tried CBD, whereas 428 (70%) endorsed CBD use. Two recent studies found a prevalence of CBD use in patients with arthritis to be between 24 and 57% which is lower than our findings (Deckey et al, 2021, Nowell, 2019. The authors feel it is unlikely that 70% of patients with arthritis in the general population have tried CBD.…”

Section: Discussioncontrasting

confidence: 91%

Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study

et al. 2022

View full text Add to dashboard Cite

Introduction An estimated 54 million Americans currently suffer from debilitating arthritis. Patients who have exhausted conservative measures can be subject to chronic pain and resort to symptomatic management with anti-inflammatories, acetaminophen, and opioids. Cannabidiol (CBD) is a non-psychoactive cannabinoid that has shown promise in preclinical studies to reduce inflammation and pain associated with arthritis. The purpose of this study was to explore patient perceived effects of cannabidiol on symptoms of arthritis. Methods A novel anonymous questionnaire was created to evaluate perceived efficacy of cannabidiol for the treatment of arthritis. A self-selected convenience sample (N=428) was recruited through online methods including social media accounts and newsletters (The Arthritis Foundation and Savvy Cooperative) between May 5, 2020, and November 5, 2020. Statistical analysis was performed to determine differences between types of arthritis and improvements in quality-of-life symptoms. Furthermore, a regression analysis was performed to identify variables associated with decreasing or discontinuing other medications. Results CBD use was associated with improvements in pain (83%), physical function (66%), and sleep quality (66%). Subgroup analysis by diagnosis type (osteoarthritis, rheumatoid, or other autoimmune arthritis) found improvements among groups for physical function (P=0.013), favoring the osteoarthritis group. The overall cohort reported a 44% reduction in pain after CBD use (P<0.001). The osteoarthritis group had a greater percentage reduction (P=0.020) and point reduction (P<0.001) in pain compared to rheumatoid arthritis and other autoimmune arthritis. The majority of respondents reported a reduction or cessation of other medications after CBD use (N=259, 60.5%): reductions in anti-inflammatories (N=129, 31.1%), acetaminophen (N=78, 18.2%), opioids (N=36, 8.6%) and discontinuation of anti-inflammatories (N=76, 17.8%), acetaminophen (N=76, 17.8%), and opioids (N=81, 18.9%). Conclusion Clinicians and patients should be aware of the various alternative therapeutic options available to treat their symptoms of arthritis, especially in light of the increased accessibility to cannabidiol products. The present study found associations between CBD use and improvements in patient’s arthritis symptoms and reductions in other medications. Future research should focus on exploring the benefits of CBD use in this patient population with clinical trials.

show abstract

Section: Discussioncontrasting

confidence: 91%

Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Interestingly, nearly 30% of CBD users reported marijuana use as well (marijuana was legalized on November 30, 2020, in the state of Arizona). Overall, this is similar to both the 25% prevalence of CBD use in patients with nonoperatively treated hip and knee osteoarthritis 6 and the 16.4% incidence of use in the perioperative period around hip and knee arthroplasty. 26 Overall, the findings presented in this study are comparable with previously reported rates of marijuana use in the United States.…”

Section: Discussionsupporting

confidence: 73%

Prevalence of Cannabinoid (CBD) Use in Orthopaedic Sports Medicine Patients

Deckey

Doan

Hassebrock

et al. 2022

Orthopaedic Journal of Sports Medicine

Self Cite

View full text Add to dashboard Cite

Background: Although there is some evidence that cannabinoid (CBD) products may provide a therapeutic effect for musculoskeletal pain, little is known about the usage patterns or their prevalence of use in orthopaedic sports medicine patients. Purpose: To report the prevalence and perceived self-efficacy of CBD products in patients evaluated in an orthopaedic sports medicine clinic. Study Design: Descriptive epidemiology study. Level of evidence, 2. Methods: The study population consisted of new patients who visited an orthopaedic surgery sports medicine clinic at a large academic center for consultation with a surgeon between August 2020 and March 2021. All patients were asked to complete a survey that assessed perceived pain and effectiveness of CBD products and other nonsurgical treatment modalities using the Single Assessment Numeric Evaluation score (range, 0-100) and the Numeric Pain Rating Scale (NRS). Descriptive factors were collected via chart review. Descriptive statistics were used to characterize the data. Results: Overall, 823 patients completed the survey (45.4% female; mean age, 51 years [range, 18-87 years]; mean body mass index, 28.9 [range, 17.2-58.4]). Body areas involved included 285 shoulders, 44 elbows, 76 hips, 276 knees, 58 ankles, and 77 other. Of these patients, 19% (152/823) endorsed the use of CBD products before their initial evaluation. The mean NRS for pain was significantly different between non-CBD users and CBD users (5.6 vs 6.1; P = .029). CBD users were significantly more likely to have tried other nonoperative modalities compared with nonusers, including nonsteroidal anti-inflammatory drugs (79.6% vs 69.8%; P = .032), bracing (44.7% vs 34.6%; P = .024), steroid injections (38.8% vs 21.6%; P < .001), and physical therapy (54% vs 36.1%; P < .001). In addition, 30.9% of CBD utilizers reported marijuana use compared with 2.8% of non-CBD users ( P < .001) for management of their pain. Conclusion: In the current study, 19% of patients had used CBD products to manage joint-related issues. Sports medicine providers should be aware of this high incidence of usage and the potential interactions CBD products may have with other treatment modalities. Further studies are needed to assess the effectiveness of CBD as a therapeutic agent and the specific interactions it has with other drugs and other forms of treatment.

show abstract

“…A survey of cannabis users in Washington state demonstrated 35.8% were substituting cannabis for narcotics/opioids [ 2 ]. Adults with symptomatic hip and knee arthritis are also increasingly turning to cannabis-containing products to help with pain relief, with 20%-24% of patients self-reporting cannabis use prior to undergoing TJA [ [22] , [23] , [24] ]. This interest also extends to the perioperative period, where 1 survey demonstrated that 75% of patients in a TJA clinic are interested in using cannabis if prescribed by a physician for acute or chronic postoperative pain [ 24 ].…”

Section: Discussionmentioning

confidence: 99%